



Kang'ombe House, 5th Floor-West Wing P.O. Box 30742 Lilongwe 3, Malawi Tel: +265 (0) 1772466 Email- compcom@comesa.int

29th October 2020

CCC Merger Inquiry Notice No. 29 of 2020

Notice of Inquiry into the Proposed Acquisition of 100% of the share capital of Alex Medical Investment Limited by Tana Africa Capital II Limited

It is hereby notified in terms of Article 26(6) of the COMESA Competition Regulations (the "**Regulations**") that the COMESA Competition Commission (the "**Commission**"), after receiving a notification in terms of Article 24 of the Regulations regarding the proposed acquisition of 100% of the share capital of Alex Medical Investment Limited ("**Alex Medical**") by Tana Africa Capital II Limited ("**Tana Africa**"), intends to embark on an inquiry in terms of Article 26 of the Regulations.

The parties have submitted that the acquiring firm is Tana Africa, a company established under the laws of Mauritius under registration number C148233. Tana Africa is a corporate entity of Tana Africa corporate group. The companies affiliated to the acquiring group are involved in a number of sectors, including banking, food and agri-business, consumer goods, and telecommunication services. The acquiring group through its related parties is active in the following COMESA Member States: Egypt, Kenya, Madagascar, Malawi, Mauritius, Rwanda, Sudan, Uganda, and Zambia.

The direct target firm is Alex Medical, a company organized and existing under the laws of Mauritius with a company number 165762. It has been submitted that as part of the transaction, Alex Medical shall hold 25% of the share capital of Alexandria Healthcare Investments S.A.E. ("Alexandria Healthcare"), which shall be the indirect target company of the acquisition. Alexandria Healthcare has a direct and indirect shareholding stake and controlling interest in a group of subsidiaries that include Mabaret Al Asafra for Medical Services S.A.E., Mabaret Al Asafra Hospital - West S.A.E.; Mabaret Al Asafra Hospital - Middle S.A.E.; and Mabaret Al Asafra Labs S.A.E. The services provided by the target firms are limited to hospital services, laboratory services, medical imaging services, and ophthalmology in Egypt

The Commission will, in accordance with the provisions of the Regulations, determine, among other things, whether or not the proposed transaction is likely to substantially prevent or lessen competition within the Common Market and whether the proposed transaction is or would be contrary to the public interest as provided for under Article 26 of the Regulations.

In view of this, the Commission hereby gives notice to all interested stakeholders, including competitors, suppliers and customers of the parties to the proposed transaction to submit written representations to the Commission with regard to the subject matter of the proposed inquiry by emailing them to: <u>sbooluck@comesa.int</u>. All written representations should be sent to the Commission not later than **19th November 2020**.

If you wish to seek further details and/or clarifications on any aspect of this proposed transaction or need assistance you may get in touch with **Ms. Sandya Booluck, Senior Analyst, Mergers and Acquisitions** on Tel: +265 (0) 1 772 466 or <u>sbooluck@comesa.int</u>.

All written representations submitted to the Commission will be treated with the strictest confidentiality and will only be used for the purpose of this inquiry.